Low dose colchicine use in familial Mediterranean fever patients whose disease is under control Hastalığı kontrol altında olan ailevi Akdeniz ateşi hastalarında düşük doz kolşisin kullanımı
Journal of Turkish Society For Rheumatology, cilt.12, sa.2, ss.30-34, 2020 (Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 12 Sayı: 2
- Basım Tarihi: 2020
- Doi Numarası: 10.4274/raed.galenos.2020.69885
- Dergi Adı: Journal of Turkish Society For Rheumatology
- Derginin Tarandığı İndeksler: Scopus, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.30-34
- Anahtar Kelimeler: Familial Mediterranean fever, low dose colchicine, subclinical inflammation
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Objective: The initial dose of colchicine recommended for the treatment of familial Mediterranean fever (FMF) is 1-1.5 mg/day in adults. The aim of this study is to identify FMF patients with mild or controlled disease, who can reduce colchicine doses. Methods: International severity scoring system score (ISSF) for FMF was calculated to determine the severity of disease in FMF patients admitted to our clinic. FMF patients, those have an ISSF score ≤2, were divided into two groups regarding to their average daily colchicine dose as low dose group (<1.5 mg per/day) and standart dose group (≥1.5 mg per/day). Results: A total of 114 FMF patients [76 (67%) female and 38 (33%) male] were included in this study. It was determined that the average colchicine dose of 58 (51%) patients was low dose (<1.5 mg/d). The proportion of patients with subclinical inflammation in the low-dose colchicine group was statistically significantly higher than the standard dose colchicine group (34% and 16% respectively, p=0.031). Conclusion: In real life, a significant number of AAA patients reduce the dose of colchicine. The subclinical inflammation rate is higher in these patients. Long-term follow-up results are needed for the risk of amyloidosis.